Gastric Cancer News and Research

RSS

ASLAN, Array sign license agreement to develop ARRY-543 for solid tumors

ASLAN Pharmaceuticals Pte Ltd and Array BioPharma Inc. today announced a license agreement to develop Array's HER2 / EGFR inhibitor, ARRY-543, currently entering Phase 2 development for solid tumors.

14 Jul 2011

Trifunctional antibody Catumaxomab triggers vaccination effect against cancer

TRION Pharma GmbH has announced that the results from two different studies demonstrate catumaxomab’s capacity to activate the immune system in a way that can otherwise only be achieved through vaccination. The data were obtained by two independent research teams using catumaxomab in malignant ascites and gastric cancer, respectively. The results were recently presented at the annual meeting of the American Society of Clinical Oncology (ASCO).

6 Jun 2011

Heavy alcohol consumption linked to increased risk of gastric cancer

The results from a very well-done meta-analysis support other data generated on the risk of alcohol consumption and gastric cancer - that is - that the risk may be real for heavy alcohol consumption but not for moderate intake.

19 May 2011

Aeterna Zentaris first quarter revenues increase to $7.4 million

Aeterna Zentaris Inc., a late-stage drug development company specialized in oncology and endocrine therapy, today reported financial and operating results as at and for the first quarter ended March 31, 2011.

18 May 2011

Study: 80% of U.S. physicians use Herceptin for HER2-positive metastatic gastric cancer treatment

In just over a month following the FDA's October 2010 approval of Roche's Herceptin for HER2-positive metastatic gastric cancer, more than 80 percent of U.S. physicians report using the drug, according to new research by GfK HealthCare.

18 May 2011

Merrimack acquires development and commercialization rights to MM-398 in Europe, Asia

Merrimack Pharmaceuticals, Inc. and PharmaEngine, Inc. today announced the signing of an agreement under which Merrimack has acquired the rights to develop and commercialize MM-398 in Europe and Asia.

9 May 2011

Oncologists discuss about NCCN updated guidelines at 4th Annual Asia Scientific Congress

More than 1,800 Chinese oncology professionals attended the NCCN 4th Annual Asia Scientific Congress in Shanghai, China, on April 9, 2011, which featured expert faculty from NCCN Member Institutions and thought leaders in cancer care from major Chinese cancer centers.

25 Apr 2011

Sugar-based vaccine against Helicobacter pylori

A potential vaccine against bacteria that cause serious gastric disorders including stomach cancer may be a step closer following a pioneering study by a University of Guelph chemist.

19 Apr 2011

Keryx KRX-0401 data in colorectal cancer, multiple myeloma presented at AACR meeting

Keryx Biopharmaceuticals, Inc. today announced that two posters on KRX-0401 were presented at the 102nd annual meeting of the American Association for Cancer Research currently ongoing at the Orange County Convention Center in Orlando, Florida. Perifosine, the Company's novel, potentially first-in-class, oral anti-cancer agent that inhibits Akt activation in the phosphoinositide 3-kinase pathway, is currently in Phase 3 clinical trials for refractory advanced colorectal cancer and multiple myeloma.

6 Apr 2011

ARIAD's ponatinib potently inhibits all four FGFRs abnormally expressed in multiple cancers

ARIAD Pharmaceuticals, Inc. today announced results of preclinical studies on ponatinib, its investigational pan-BCR-ABL inhibitor, showing potent inhibition of all four members of the fibroblast growth factor receptor (FGFR) family of tyrosine kinases that are abnormally expressed in multiple cancers. ARIAD scientists are presenting the data this morning at the American Association for Cancer Research (AACR) Annual Meeting in Orlando, Florida.

5 Apr 2011

Aeterna Zentaris presents two posters on perifosine at AACR meeting

Aeterna Zentaris Inc. today announced that two posters on its lead anticancer agent, perifosine, were presented at the 102nd annual meeting of the American Association for Cancer Research currently held at the Orange County Convention Center in Orlando, Florida.

5 Apr 2011

AACR President-elect to host press conference on cancer risk factors and genetics

As cancer continues to affect one in two men and one in three women, researchers are increasing their knowledge on the known risk factors for cancer both environmentally and genetically.

5 Apr 2011

Heavy beer drinkers with specific genetic variant at increased risk of non-cardia gastric cancer

Heavy beer drinkers who have a specific genetic variant in the cluster of three genes that metabolize alcohol are at significantly higher risk of developing non-cardia gastric cancer, according to research presented at the AACR 102nd Annual Meeting 2011, held here April 2-6.

5 Apr 2011

Mersana commences XMT-1001 Phase 1b extension study in gastric cancer and non-small cell lung cancer

Mersana Therapeutics today announced the initiation of a Phase 1b extension study with its lead cancer product, XMT-1001, a novel DNA topoisomerase I inhibitor based on the company's Fleximer® polymer conjugate platform, in second-line gastric cancer and second-/third-line non-small cell lung cancer. The study will be carried out in 10 clinical centers in the US.

25 Mar 2011

Hydro-stomach CT imaging is not a reliable tool for EGC detection: Study

Traditionally, both air and tap water have been used as oral contrast agents to achieve adequate gastric distension for preoperative computed tomography imaging in patients with early gastric cancer.

16 Mar 2011

EC grants marketing authorization for Taiho's Teysuno to treat gastric cancer

Taiho Pharmaceutical Co., Ltd., and its parent company, Otsuka Holdings Co., Ltd., announced today that the European Commission has granted marketing authorization for Teysuno, a novel oral anti-cancer agent indicated for the treatment of adults with advanced gastric cancer when given in combination with cisplatin.

15 Mar 2011

Synta fourth-quarter total collaboration revenue decreases to $3.0 million

Synta Pharmaceuticals Corp., a biopharmaceutical company focused on discovering, developing, and commercializing small molecule drugs to treat severe medical conditions, today reported fourth-quarter and full-year 2010 financial results, provided an update on recent progress with its programs, and announced 2011 objectives.

11 Mar 2011

First urinary metabolomic investigation in gastric cancer using gas chromatography/mass spectrometry

Metabolomics is a post-genomic research field for analysis of low molecular weight compounds in biological systems, and its approaches offer an analysis of metabolite level changes in biological samples. Recently, metabolomic method has shown great potentials in identifying the new diagnostic markers and therapeutic targets for cancers. However, metabolomic studies on cancer metastasis remain scarce.

9 Mar 2011

Patrys succeeds in obtaining commercial yields for its anti-cancer antibody therapeutic

Patrys Limited (ASX: PAB), which is developing a new class of antibody molecules for the treatment of cancer, is pleased to announce success in obtaining commercial production yields for natural human antibody PAT-SC1, facilitating the advancement of this promising product toward a second human clinical trial for the treatment of cancer.

8 Mar 2011

Turmeric may be 'the right spice' to fight colon cancer

Turmeric, a bright yellow spice from south Asia belonging to the ginger family, is the main ingredient in curries - and ancient wisdom suggests that it's also good for your health. Taking this wisdom to the laboratory, Tel Aviv University researchers have discovered that turmeric's active ingredient called curcumin amplifies the therapeutic activity of highly toxic anti-inflammatory drugs used to fight colon cancer when used at high doses.

3 Mar 2011

Gastric Cancer News and Research

ASLAN, Array sign license agreement to develop ARRY-543 for solid tumors

Trifunctional antibody Catumaxomab triggers vaccination effect against cancer

Heavy alcohol consumption linked to increased risk of gastric cancer

Aeterna Zentaris first quarter revenues increase to $7.4 million

Study: 80% of U.S. physicians use Herceptin for HER2-positive metastatic gastric cancer treatment

Merrimack acquires development and commercialization rights to MM-398 in Europe, Asia

Oncologists discuss about NCCN updated guidelines at 4th Annual Asia Scientific Congress

Sugar-based vaccine against Helicobacter pylori

Keryx KRX-0401 data in colorectal cancer, multiple myeloma presented at AACR meeting

ARIAD's ponatinib potently inhibits all four FGFRs abnormally expressed in multiple cancers

Aeterna Zentaris presents two posters on perifosine at AACR meeting

AACR President-elect to host press conference on cancer risk factors and genetics

Heavy beer drinkers with specific genetic variant at increased risk of non-cardia gastric cancer

Mersana commences XMT-1001 Phase 1b extension study in gastric cancer and non-small cell lung cancer

Hydro-stomach CT imaging is not a reliable tool for EGC detection: Study

EC grants marketing authorization for Taiho's Teysuno to treat gastric cancer

Synta fourth-quarter total collaboration revenue decreases to $3.0 million

First urinary metabolomic investigation in gastric cancer using gas chromatography/mass spectrometry

Patrys succeeds in obtaining commercial yields for its anti-cancer antibody therapeutic

Turmeric may be 'the right spice' to fight colon cancer

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News